Efficacy and safety of Infliximab for steroid-resistant immune-related adverse events: A retrospective study.
diarrhea/colitis
immune checkpoint inhibitor
immune-related adverse event
infliximab
steroid resistance
Journal
Molecular and clinical oncology
ISSN: 2049-9450
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
06
04
2020
accepted:
12
01
2021
entrez:
8
3
2021
pubmed:
9
3
2021
medline:
9
3
2021
Statut:
ppublish
Résumé
The present study investigated outcomes of infliximab (IFX) treatment among 8 Japanese patients with various types of cancer (4 with malignant melanoma, 3 with lung cancer and 1 with renal cancer) who developed severe steroid-resistant immune-related adverse events (irAEs) in association with immune checkpoint inhibitors (ICIs) to determine its efficacy and safety. Information, including patient background, treatment progress, examination data and imaging data, was collected retrospectively from electronic medical records. Adverse reactions were evaluated using the Common Terminology Criteria for Adverse Events version 4.0. Specific ICIs used were anti-PD-1, anti-PD-L1 and anti-CTLA-4 antibody preparations in 7, 2 and 5 patients, respectively. Specific irAEs included grade 3 diarrhea/colitis in 7 patients and disseminated intravascular coagulation and myocarditis attributed to autoimmune activation in 1 patient. The median duration between systemic steroid and IFX treatments was 9 (range, 2-39) days. A total of 3 patients responded to IFX, 1 of whom responded after one dose and 2 responded after two doses. Respective diseases improved to grade 0 after a median of 18 (range, 9-32) days. No AEs were attributable to IFX. Additionally, anti-cytomegalovirus (CMV) and antibacterial agents were administered in parallel given the presence of CMV and
Identifiants
pubmed: 33680456
doi: 10.3892/mco.2021.2227
pii: MCO-0-0-02227
pmc: PMC7890436
doi:
Types de publication
Journal Article
Langues
eng
Pagination
65Informations de copyright
Copyright: © Kadokawa et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Nature. 2019 May;569(7756):428-432
pubmed: 31043740
J Clin Oncol. 2006 May 20;24(15):2283-9
pubmed: 16710025
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
World J Gastrointest Pharmacol Ther. 2019 Jan 21;10(1):29-34
pubmed: 30697447
Cancer Immun. 2010 Nov 24;10:11
pubmed: 21090563
N Engl J Med. 2018 Jan 11;378(2):158-168
pubmed: 29320654
Cancer Immunol Immunother. 2017 May;66(5):581-592
pubmed: 28204866
N Engl J Med. 2011 Jun 30;364(26):2517-26
pubmed: 21639810
Clin Gastroenterol Hepatol. 2017 Apr;15(4):e80-e81
pubmed: 27664866
Case Rep Oncol Med. 2019 Jul 22;2019:9069354
pubmed: 31428491
Cancer Biother Radiopharm. 2009 Jun;24(3):321-5
pubmed: 19538054
Aliment Pharmacol Ther. 2015 Aug;42(4):406-17
pubmed: 26079306
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
Lancet. 2014 Sep 20;384(9948):1109-17
pubmed: 25034862
Melanoma Res. 2013 Jun;23(3):227-30
pubmed: 23458760
Asia Pac J Clin Oncol. 2017 Oct;13(5):e284-e290
pubmed: 27981760
Am J Case Rep. 2018 Mar 27;19:360-364
pubmed: 29581417
Case Rep Gastroenterol. 2018 Nov 28;12(3):704-708
pubmed: 30631256
Gut. 2018 Nov;67(11):2056-2067
pubmed: 30131322
J Immunother Cancer. 2018 Oct 11;6(1):103
pubmed: 30305177
J Clin Oncol. 2012 Jul 20;30(21):2691-7
pubmed: 22614989
Eur J Cancer. 2017 Nov;86:248-256
pubmed: 29055840
Lancet Oncol. 2015 Mar;16(3):257-65
pubmed: 25704439
N Engl J Med. 2013 Jul 11;369(2):134-44
pubmed: 23724846
Cancer Res. 2016 Sep 15;76(18):5288-301
pubmed: 27503925